Aytu BioScience, Inc. (OTC: AYTU) is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. Aytu is initially concentrating on prostate cancer, male sexual dysfunction and male infertility and plans to expand into other urological indications for which there are significant medical needs. The company currently markets ProstaScint® (Capromab Pendetide), the only radioimaging agent indicated to detect prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. For more information, visit the company’s website at www.aytubio.com.